View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 28, 2019updated 02 Nov 2021 7:10am

Zimmer Biomet obtains FDA nod to use knee system in robotic surgery

Musculoskeletal healthcare company Zimmer Biomet has received 510(k) clearance from the US Food and Drug Administration (FDA) for the use of its ROSA Knee System in robotically-assisted total knee replacement procedures.

Musculoskeletal healthcare company Zimmer Biomet has received 510(k) clearance from the US Food and Drug Administration (FDA) for the use of its ROSA Knee System in robotically-assisted total knee replacement procedures.

The new system offers 3D pre-operative planning tools along with real-time, intraoperative data on soft-tissue and bone anatomy.

ROSA Knee is meant to enhance bone cut accuracy and range of motion gap analysis in order to potentially boost flexion and restore natural joint movement.

“The ROSA Knee system offers intraoperative, real-time mapping of a patient’s anatomy and motion, allowing surgeons to personalise surgeries and improve outcomes.”

The robotically-assisted surgical system is designed to deliver continuous data analysis to help surgeons in complex decision-making and facilitate use of computer and software technology for control and movement of surgical instruments.

It leverages Zimmer Biomet X-Atlas imaging protocol, which enables X-ray preoperative imaging to generate a 3D model and plan of patient’s bone anatomy.

In addition, the ROSA Knee system offers intraoperative, real-time mapping of a patient’s anatomy and motion, allowing surgeons to personalise surgeries and improve outcomes.

Zimmer Biomet Orthopedics group president Ivan Tornos said: “We are excited for the launch of ROSA Knee, which brings together Zimmer Biomet’s robotics technology with our industry-leading knee implants to help surgeons personalise surgical procedures for their patients.

“Zimmer Biomet is committed to leading the industry in bringing differentiated and holistic solutions to market that address the needs of our customers and improve patient outcomes.”

The company’s portfolio includes orthopaedic reconstructive, sports medicine, biologics, extremities, trauma, spine, craniomaxillofacial and thoracic products; dental implants; and associated surgical products.

In October last year, Zimmer Biomet collaborated with Apple to help knee and hip replacement surgery patients using Apple Watch and iPhone.

The partners developed the Zimmer Biomet mymobility app, with the aim of using Apple Watch to improve how patients communicate with their surgical care teams.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU